|
INPPL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.23149999589722E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.78649999968717E-07 |
| Normal-vs-Stage2 |
5.220300E-02 |
| Normal-vs-Stage3 |
4.07309996841576E-09 |
| Normal-vs-Stage4 |
3.3805999999359E-08 |
| Stage1-vs-Stage2 |
6.109800E-02 |
| Stage1-vs-Stage3 |
3.252400E-02 |
| Stage1-vs-Stage4 |
5.103700E-02 |
| Stage2-vs-Stage3 |
1.084190E-03 |
| Stage2-vs-Stage4 |
2.000000E-03 |
| Stage3-vs-Stage4 |
7.334000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.58830001875765E-09 |
| Normal-vs-AfricanAmerican |
5.523600E-03 |
| Normal-vs-Asian |
1.52688999999206E-05 |
| Caucasian-vs-AfricanAmerican |
3.147600E-01 |
| Caucasian-vs-Asian |
6.645600E-01 |
| AfricanAmerican-vs-Asian |
4.635800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.19299999995692E-06 |
| Normal-vs-Female |
1.98899999803714E-08 |
| Male-vs-Female |
6.570000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.04310000004215E-06 |
| Normal-vs-Age(41-60Yrs) |
7.87999999696254E-08 |
| Normal-vs-Age(61-80Yrs) |
1.97079999999517E-05 |
| Normal-vs-Age(81-100Yrs) |
7.081300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.730000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.715600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.851800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.198200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.093200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.654000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.42739999995112E-06 |
| Classical-VS-Follicular |
1.66299999992958E-07 |
| Classical-VS-Other |
5.431200E-01 |
| Classical-VS-Normal |
1.86130000301432E-08 |
| Tall-VS-Follicular |
5.83122439223871E-12 |
| Tall-VS-Other |
5.801600E-02 |
| Tall-VS-Normal |
2.78665979180914E-14 |
| Follicular-VS-Other |
3.214600E-01 |
| Follicular-VS-Normal |
2.888200E-01 |
| Other-VS-Normal |
7.236000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.54215000000013E-05 |
| Normal-vs-N1 |
2.276099997367E-08 |
| N0-vs-N1 |
1.300420E-02 |
|
|
